Carbonic Anhydrase Inhibitors: Effects & Uses

What Are Carbonic Anhydrase Inhibitors?

Carbonic anhydrase inhibitors (CAIs) are a class of medications that block the enzyme carbonic anhydrase. This enzyme is widely distributed throughout the human body and catalyzes a key biochemical reaction: the conversion of carbon dioxide (CO2) and water (H2O) into carbonic acid (H2CO3), which then dissociates into bicarbonate and hydrogen ions. By inhibiting this enzyme, carbonic anhydrase inhibitors interfere with several important physiological processes.

Mechanism of Action

Carbonic anhydrase is found in many tissues, including the kidneys, eyes, brain, and red blood cells. Carbonic anhydrase inhibitors bind to the active site of the enzyme, blocking its function. The effects differ depending on the site of action:

• In the kidneys: Inhibition of carbonic anhydrase reduces the reabsorption of sodium bicarbonate in the proximal tubule, leading to increased urinary excretion of bicarbonate, sodium, and water. This produces a diuretic effect and may cause metabolic acidosis (a decrease in blood pH).
• In the eye: In the ciliary body of the eye, carbonic anhydrase plays a role in the production of aqueous humor. Inhibiting the enzyme reduces aqueous humor production, thereby lowering intraocular pressure.
• In the brain: The exact mechanisms are not yet fully understood, but alterations in pH levels and ion transport within the brain are thought to contribute to the antiepileptic effects of some agents in this class.

Indications (Medical Uses)

Carbonic anhydrase inhibitors are used for several medical indications:

• Glaucoma: This is the most common indication. Both systemic agents (e.g., acetazolamide) and topical agents applied directly to the eye (e.g., dorzolamide, brinzolamide) reduce elevated intraocular pressure and protect the optic nerve.
• Epilepsy: Acetazolamide is used as adjunct therapy for certain types of epilepsy, particularly when other antiepileptic drugs have not provided sufficient control.
• Acute Mountain Sickness: Acetazolamide is used for the prevention and treatment of altitude sickness, as it stimulates breathing and facilitates acclimatization to high altitudes.
• Idiopathic Intracranial Hypertension: In cases of elevated intracranial pressure without an identifiable cause, acetazolamide can help reduce cerebrospinal fluid pressure.
• Periodic Paralysis: Certain forms of this rare condition may be managed with carbonic anhydrase inhibitors.

Key Active Substances

The most commonly used carbonic anhydrase inhibitors include:

• Acetazolamide: The classic systemically administered (oral tablet) carbonic anhydrase inhibitor. Used for glaucoma, epilepsy, and altitude sickness.
• Dorzolamide: A topical carbonic anhydrase inhibitor in the form of eye drops, used primarily in glaucoma treatment.
• Brinzolamide: Also a topical carbonic anhydrase inhibitor in eye drop form for the management of glaucoma.
• Methazolamide: Another systemic carbonic anhydrase inhibitor used mainly for glaucoma.
• Zonisamide and Topiramate: Newer antiepileptic drugs that also possess carbonic anhydrase inhibitory properties among their mechanisms of action.

Dosage and Administration

Dosage varies depending on the specific agent, route of administration, and indication. Systemic preparations (tablets) are generally taken one to four times daily. Eye drops are typically instilled two to three times daily into the affected eye. The exact dosage is always determined by the treating physician and should not be altered without medical advice.

Side Effects

Carbonic anhydrase inhibitors, particularly when taken systemically, can cause a range of side effects:

• Common side effects: Tingling or numbness in the hands and feet (paresthesia), increased urination (due to the diuretic effect), taste disturbances, loss of appetite, nausea, and fatigue.
• Metabolic acidosis: Increased excretion of bicarbonate can lower blood pH, potentially causing symptoms such as shortness of breath, confusion, and general malaise.
• Electrolyte imbalances: Low potassium levels (hypokalemia) may occur, which can lead to muscle cramps and cardiac arrhythmias.
• Kidney stones: Prolonged use increases the risk of kidney stones, particularly calcium phosphate stones.
• Allergic reactions: Since carbonic anhydrase inhibitors are structurally related to sulfonamide antibiotics, cross-reactions may occur in patients with known sulfonamide hypersensitivity.
• Topical use (eye drops): Local irritation, burning or stinging in the eye, and a bitter taste in the mouth are possible.

Contraindications and Drug Interactions

Carbonic anhydrase inhibitors should not be used, or should be used with particular caution, in the following situations:

• Known hypersensitivity to sulfonamides
• Severe kidney or liver disease
• Low blood potassium (hypokalemia) or low blood sodium (hyponatremia)
• Pregnancy and breastfeeding (only after consulting a physician)

Important interactions exist with other diuretics, cardiac glycosides (e.g., digoxin), lithium, and certain antiepileptic drugs. Concurrent use of high-dose aspirin may increase the toxicity of acetazolamide.

References

1. Mutschler, E. et al. - Mutschler Arzneimittelwirkungen: Pharmakologie, Klinische Pharmakologie, Toxikologie, 11th Edition. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2020.
2. European Glaucoma Society - Terminology and Guidelines for Glaucoma, 5th Edition. PubliComm, 2020. Available at: https://www.eugs.org
3. Supuran, C.T. - Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Reviews Drug Discovery, 7(2):168-181, 2008. DOI: 10.1038/nrd2467